Orchestration of human multi-lineage hematopoietic cell development by humanized in vivo bone marrow models
Renou L, Sun W, Friedrich C, Galant K, Conrad C, Consalus A, Plantier E, Schallmoser K, Krisch L, Barroca V, Devanand S, Dechamps N, Reinisch A, Martinovic J, Magnani A, Faivre L, Lewandowski D, Calvo J, Perie L, Kosmider O, Pflumio F. Hemasphere. 2025 Apr 22;9(4):e70120. doi: 10.1002/hem3.70120. PMID: 40265169; PMCID: PMC12012840.
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A, Gauthier N, Short N, Bonnet S, Sasaki K, Khalife-Hachem S, Swaminathan M, Micol JB, Pasquier F, Marzac C, Roos-Weil D, Pascal L, Daver N, Kadia T, Bouscary D, Ravandi F, Pages A, Kantarjian H, De Botton S, DiNardo C. Blood Cancer J. 2025 Apr 17;15(1):68. doi: 10.1038/s41408-025-01269-x. PMID: 40246832; PMCID: PMC12006504.
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a genome-edited human iPSC model of pediatric leukemia initiation
Boudia F, Baille M, Babin L, Aid Z, Robert E, Rivière J, Galant K, Alonso-Pérez V, Anselmi L, Arkoun B, Abermil N, Marzac C, Bertuccio SN, de Prémesnil A, Lopez CK, Eeckhoutte A, Naimo A, Leite B, Catelain C, Metereau C, Gonin P, Gaspar N, Schwaller J, Bernard OA, Raslova H, Gaudry M, Marchais A, Lapillonne H, Petit A, Pflumio F, Arcangeli ML, Brunet E, Mercher T. Blood. 2025 Apr 3;145(14):1510-1525. doi: 10.1182/blood.2024024505. PMID: 39656971.
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders
Fandrei D, Pegliasco J, Pasquier F, Ibrahim N, Kfoury M, Berthon C, Heiblig M, Lebon D, Marçais A, Meunier M, Al Jijakli A, Lemasle E, Chantepie S, Pautas C, Dumas PY, Salanoubat C, Carp D, Loyaux R, Quivoron C, Pages A, Job B, Jelin R, Jules-Clement G, Antony-Debré I, Renneville A, Cotteret S, Itzykson R, Dombret H, Duployez N, Droin N, Leary A, Marzac C, Bernard E, Micol JB. Clin Cancer Res. 2025 Mar 31. doi: 10.1158/1078-0432.CCR-24-3683. Epub ahead of print. PMID: 40162927.
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis.
Marchand V, Laplane L, Valensi L, Plo I, Aglave M, Silvin A, Pasquier F, Porteu F, Vainchenker W, Selimoglu-Buet D, Droin N, Raslova H, Marcel V, Diaz JJ, Fontenay M, Solary E. iScience. 2024 Dec 2;28(1):111522. doi: 10.1016/j.isci.2024.111522. PMID: 39811665; PMCID: PMC11732210.
High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
Calvo J, Naguibneva I, Kypraios A, Gilain F, Uzan B, Gaillard B, Bellenger L, Renou L, Antoniewski C, Lapillonne H, Petit A, Ballerini P, Mancini S J.C, Marchand T, Peyron JF, Pflumio F. Leukemia 39, 323–336 (2025). https://doi.org/10.1038/s41375-024-02473-7
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.
Deschamps P, Wacheux M, Gosseye A, Morabito M, Pagès A, Lyne AM, Alfaro A, Rameau P, Imanci A, Chelbi R, Marchand V, Renneville A, Patnaik MM, Lapierre V, Badaoui B, Wagner-Ballon O, Berthon C, Braun T, Willekens C, Itzykson R, Fenaux P, Thépot S, Etienne G, Elvira-Matelot E, Porteu F, Droin N, Perié L, Laplane L, Solary E, Selimoglu-Buet D. J Clin Invest. 2024;134(22):e180738. https://doi.org/10.1172/JCI180738.
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathways .
Hidaoui D, Porquet A, Chelbi R, Bohm M, Polyzou A, Alcazer V, Depil S, Imanci A, Morabito M, Renneville A, Selimoglu-Buet D, Thépot S, Itzykson R, Laplane L, Droin N, Trompouki E, Elvira-Matelot E, Solary E, Porteu F. Commun Biol. 2024 Nov 22;7(1):1555. doi: 10.1038/s42003-024-07214-1. PMID: 39578583; PMCID: PMC11584673.
High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
Calvo J, Naguibneva I, Kypraios A, Gilain F, Uzan B, Gaillard B, Bellenger L, Renou L, Antoniewski C, Lapillonne H, Petit A, Ballerini P, Mancini SJ, Marchand T, Peyron JF, Pflumio F. Leukemia. 2025 Feb;39(2):323-336. doi: 10.1038/s41375-024-02473-7. Epub 2024 Nov 24. PMID: 39580584; PMCID: PMC11794132.
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia.
Alonso-Pérez V, Galant K, Boudia F, Robert E, Aid Z, Renou L, Barroca V, Devanand S, Babin L, Rouiller-Fabre V, Moison D, Busso D, Piton G, Metereau C, Abermil N, Ballerini P, Hirsch P, Haddad R, Martinovic J, Petit A, Lapillonne H, Brunet E, Mercher T, Pflumio F. Mol Cancer. 2024 Sep 20;23(1):204. doi: 10.1186/s12943-024-02110-y. PMID: 39304903; PMCID: PMC11414260.
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.
Geoerger B, Schiff M, Penard-Lacronique V, Darin N, Saad SM, Duchon C, Lamazière A, Desmons A, Pontoizeau C, Berlanga P, Ducassou S, Yen K, Su M, Schenkein D, Ottolenghi C, De Botton S. Nat Med. 2023 Jun;29(6):1358-1363. doi: 10.1038/s41591-023-02382-9. Epub 2023 May 29. PMID: 37248298.
Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A, Bernard E, Micol JB. Bull Cancer. 2023 Jun 28:S0007-4551(23)00277-1. doi: 10.1016/j.bulcan.2023.02.022. Epub ahead of print. PMID: 37391357.
ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis.
Basso-Valentina F*, Donada A*, Manchev VT, Lisetto M, Balayn N, Martin JE, Muller D, Marin Oyarzun CP, Duparc H, Arkoun A, Cumin A, Faivre L, Droin N, Biunno I, Balduini A, Debili N, Antony-Debré I, Marty C, Vainchenker W, Plo I, Favier R, Raslova H. Haematologica. 2023 Aug 1;108(8):2130-2145.
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Rodriguez-Meira A*, Norfo R*, Wen S*, Chédeville A*, Rahman H, O’Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, Brierley C, Martin JE, Demeule C, Bashton M, Sousos N, Moralli D, Subha Meem L, Carrelha J, Wu B, Hamblin A, Guermouche H, Pasquier F, Marzac C, Girodon F, Vainchenker W, Drummond M, Harrison C, Chapman JR, Plo I, Jacobsen SEW, Psaila B, Thongjuea S, Antony-Debré I§, Mead AJ§. Nature Genetics. 2023 Sep 4. doi: 10.1038/s41588-023-01480-1. Epub ahead of print.
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.
Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, Fagnan A, Thirant C, Federici L, Touchard L, Lecluse Y, Jetten A, Geoerger B, Lapillonne H, Solary E, Gaudry M, Meshinchi S, Pflumio F, Auberger P, Lobry C, Petit A, Jacquel A, Mercher T. Leukemia. 2023 Mar;37(3):571-579. doi: 10.1038/s41375-022-01800-0. Epub 2022 Dec 30. PMID: 36585521.
The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions.
Henry E, Picou F, Barroca V, Dechamps N, Sobrino S, Six E, Gobeaux C, Auberger P, Hérault O, Pflumio F, Arcangeli ML. Stem Cells Transl Med. 2023 Aug 24:szad049. doi: 10.1093/stcltm/szad049. Online ahead of print.PMID: 37616262
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
Marques Da Costa ME, Zaidi S, Scoazec JY, Droit R, Lim WC, Marchais A, Salmon J, Cherkaoui S, Morscher RJ, Laurent A, Malinge S, Mercher T, Tabone-Eglinger S, Goddard I, Pflumio F, Calvo J, Redini F, Entz-Werlé N, Soriano A, Villanueva A, Cairo S, Chastagner P, Moro M, Owens C, Casanova M, Hladun-Alvaro R, Berlanga P, Daudigeos-Dubus E, Dessen P, Zitvogel L, Lacroix L, Pierron G, Delattre O, Schleiermacher G, Surdez D, Geoerger B. Commun Biol. 2023 Sep 18;6(1):949. doi: 10.1038/s42003-023-05320-0.PMID: 37723198
SRSF2-P95H diminue la signalisation JAK/STAT dans les cellules hématopoïétiques et retarde le développement de la myélofibrose chez la souris
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, Signolle N, Marchand V, Droin N, Hoogenboezem R, Schneider RK, Penson A, Abdel-Wahab O, Giraudier S, Pasquier F, Marty C, Plo I, Villeval JL, Constantinescu SN, Porteu F, Vainchenker W, Solary E. SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023 Apr 26. doi: 10.1038/s41375-023-01878-0. Epub ahead of print. PMID: 37100881.